Inoue K, Inoue J, Kunimatsu-Sanuki S, et al. - Researchers sought to retrospectively assess the short-term effectiveness of omidenepag isopropyl (EYBELIS 0.002%) by evaluating its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG). The sample consisted of 54 NTG patients (54 eyes), mean age 55.0 ±  14.1 years, who were newly administrated with omidenepag isopropyl. According to findings, IOP in patients with NTG was significantly decreased after administration of omidenepag isopropyl. In 7.4% of patients, however, adverse reactions occurred.